Cisplatin pharmacokinetic
WebCisplatin was administered to seven patients with advanced cancer in divided doses of 40 mg/m2 body surface daily for 5 consecutive days. The pharmacokinetics of total Pt was studied on the days 1, 3 and 5 of infusion. The renal function was assessed through the parameters usually applied in the cli … WebCisplatin is a platinum-based agent whose nephrotoxicity is thought related to the chloride in the cis position. Cisplatin gains entry into tubular cells via uptake by the OCT-2 …
Cisplatin pharmacokinetic
Did you know?
WebJul 22, 2024 · Pharmacokinetics not affected by mild (Cl cr 50–80 mL/minute), moderate (Cl cr 30 to <50 mL/minute), or severe (Cl cr <30 mL/minute) renal impairment. Pharmacokinetics have not been evaluated in patients with renal impairment requiring dialysis. Common Adverse Effects
WebJan 16, 2016 · Pharmacokinetic interactions were evaluated.Methods Plasma pazopanib and ultrafilterable cisplatin concentrations were obtained in 32 patients treated according to four levels of dose corresponding to 200, 400 or 600 mg daily dose of pazopanib and 60 or 75 mg/m2 of cisplatin. Two sequences of treatment… View on Springer ncbi.nlm.nih.gov WebMar 1, 1998 · The pharmacokinetics[PK] of cisplatin are complicated. It is demonstrated that the analysis of PK for free platinum is appropriate to predict the pharmacodynamic [PD] …
WebJun 19, 2024 · Cisplatin concentrations were determined in plasma and ultrafiltrate samples collected on each of six cycles of a monotherapy regimen, beginning with a dose of 1.6 mg/kg at 16 days of age. Pharmacokinetic data were analyzed to generate clearance (CL) and area under the curve (AUC 0–∞) for each administration. WebMethods: Pharmacokinetic and demographic data were collected from 32 adult patients (20 males/12 females, age range 47-76 years) receiving 30-min infusions …
WebCisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities Br J Cancer. 1992 Jun;65(6):898-902. doi: 10.1038/bjc.1992.188. Authors H J Guchelaar 1 , H J Hoekstra, E G de Vries, D R Uges, J W Oosterhuis, H Schraffordt Koops. Affiliation 1 Department of ...
WebAug 20, 2024 · cisplatin AND (pharmacokinetics OR population pharmacokinetics OR NONMEM) Statistical analysis and evaluation of the candidate models The unbound cisplatin PK parameter estimates and standard errors (from the bootstrap validation, where available), were extracted from the studies reporting the population PK models of cisplatin. in about russellWebJan 16, 2016 · Purpose A phase I study combining daily oral pazopanib and cisplatin (given iv every 3 weeks) was performed in order to determine the maximum tolerated dose of both drugs in combination. Pharmacokinetic interactions were evaluated. Methods Plasma pazopanib and ultrafilterable cisplatin concentrations were obtained in 32 patients … in absence of afkortingWebMar 2, 2005 · The pharmacokinetic model distinguished between active drug and their inactive (inert) metabolites in plasma and CSF. INTRODUCTION The platinum analogues, cisplatin and carboplatin, are chemically reactive anticancer drugs that produce a cytotoxic effect through platination of DNA and the formation of cross-links. inasal ownerWebFeb 16, 2024 · severe or ongoing nausea and vomiting; vision problems, pain behind your eyes; hearing problems, ringing in your ears; pain, redness, swelling, or skin … in absence in latinWebApr 10, 2024 · Triple-negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer and constitutes 10–20% of all breast cancer cases. Even though platinum-based drugs such as cisplatin and carboplatin are effective in TNBC patients, their toxicity and development of cancer drug resistance often hamper their clinical use. … in absence by h.a. vaughanWebMay 1, 2001 · Population Pharmacokinetic Analysis of Cisplatin and Its Metabolites in Cancer Patients: Possible Misinterpretation of Covariates for Pharmacokinetic Parameters Calculated from the Concentrations of Unchanged Cisplatin, Ultrafiltered Platinum and Total Platinum Kazuhiko Hanada, Kazuyuki Nishijima, Hiroyasu Ogata, Shinji Atagi, Masaaki … inaset offset specificationWebCISPLATIN Although they are members of the same chemical family, cis- platin is considered to be superior therapy for specifictumor typescomparedwithcarboplatin.Unfortunately,nephrotoxicity is the dose-limiting side effect of this very effective chemother- apeutic agent (17–19). inasan science reports impact factor